|
| |
| | Coagulation Factor Assays |
 | | Deficiencies of factor(s) VIII, IX, XI, and/or XII (intrinsic pathway) | | | In hemophilia, <1% factor VIII or IX produces severe hemophilia with spontaneous bleeding, 1% to 5% produces moderate bleeding, and >5% is considered mild hemophilia in which bleeding occurs primarily with trauma or surgery rather than spontaneously. | | | Factors XI and XII have the longest half-lives and therefore are often the last to be affected. |
|
http://www.mgh.harvard.edu/labmed/lab/coag/handbook/CO001100.htm
(3048 words)
|
|
| |
| | Coagulation Factor Assays |
| | Deficiencies of factor(s) VIII, IX, XI, and/or XII (intrinsic pathway) | | | Factor VIII, IX, XI, and XII assays are PTT-based. | | | Factors XI and XII have the longest half-lives and therefore are often the last to be affected. |
|
http://www.mgh.harvard.edu/labmed/lab/coag/handbook/CO001100.htm
(3048 words)
|
|
| |
| | 1.4.4 The coagulation mechanism |
| | Factor X is the first molecule of the common pathway and is activated by a complex of molecules containing activated factor IX, factor VIII, calcium, and phospholipid which is provided by the platelet surface, where this reaction usually takes place. | | | There is evidence that the Hageman factor can autoactivate, thus the pathway is self-amplifying once triggered (compare with the alternative pathway of complement). | | | Eventually the intrinsic pathway activates factor X, a process that can also be brought about by the extrinsic pathway. |
|
http://nic.sav.sk/logos/books/scientific/node29.html
(3048 words)
|
|
| |
| | article.aspx?articleid=100096 |
| | Factor X is the first molecule of the common pathway and is activated by a complex of molecules containing activated factor IX, factor VIII, calcium and phospholipid, which is provided by the platelet surface, where this reaction usually takes place. | | | The intrinsic pathway ultimately activates factor X, a process which can also be brought about by the extrinsic pathway. | | | There is evidence that the Hageman factor can autoactivate, thus the pathway is self-amplifying. |
|
http://www.fantalizee.com/article.aspx?articleid=100096
(5742 words)
|
|
| |
| | Activated Partial Thromboplastin Time |
| | Factor deficiencies that prolong PTT: The PTT is more sensitive to deficiencies of the intrinsic pathway (factors VIII, IX, XI, XII, prekallikrein, HMWK) than it is to deficiencies of the common pathway (fibrinogen, and factors II, V, and X). | | | The PTT is more sensitive to intrinsic pathway factor deficiencies than to common pathway factor deficiencies. | | | Therefore, in these situations, an alternative assay, such as the Heparin Antifactor Xa Assay, should be used rather than the PTT to monitor heparin. |
|
http://www.mgh.harvard.edu/labmed/lab/coag/handbook/co003400.htm
(5742 words)
|
|
| |
| | Factor IX - Wikipedia, the free encyclopedia |
| | Factor IX is inactive unless activated by factor XIa (of the contact pathway) or factor VIIa (of the tissue factor pathway). | | | Over 100 mutations of factor IX have been described; some cause no symptoms, but many lead to a significant bleeding disorder. | | | Deficiency of factor IX causes Christmas disease (hemophilia B). |
|
http://en.wikipedia.org/wiki/Factor_IX
(208 words)
|
|
| |
| | Clinical Trial: Cooperative Study of Factor VIII Inhibitors |
| | The rationale for Factor IX was that it bypassed the defect in Factor VIII caused by the inhibitor. | | | Because of lack of information on the natural course of patients with Factor VIII inhibitors, the relative efficacy of various modes of therapy was not established. | | | It was intended at the very outset of the Factor VIII study that therapeutic trials involving patients with inhibitors would not be a prime function, but that such studies would be monitored if necessary. |
|
http://clinicaltrials.gov/ct/show/NCT00000582?order=8
(498 words)
|
|
| |
| | Afibrinogenemia, Congenital |
| | Factor IX Deficiency is a severe genetic bleeding disorder that resembles classic Hemophilia A. Factor IX is a component of the blood clotting substance thromboplastin. | | | Hageman Factor Deficiency is a rare genetic blood disorder. | | | Factor XIII Deficiency is a very rare inherited disorder that prevents the blood from clotting normally. |
|
http://hw.healthdialog.com/kbase/nord/nord940.htm
(498 words)
|
|
| |
| | Treatment - Boston Hemophilia Center - Clinical Services - Children's Hospital Boston |
| | Hemophilia B, caused by a deficiency of factor IX, is treated with intravenous infusion of plasma-derived or synthetic recombinant factor IX. | | | Factor VIII products are made by either purification from human plasma (the liquid part of blood) or by synthetic processes. | | | Available as a nose spray or by intravenous infusion, this hormone increases the levels of factor VIII in the blood. |
|
http://www.childrenshospital.org/clinicalservices/Site1971/mainpageS1971P16.html
(293 words)
|
|
| |
| | BEAUMAN2 |
| | Injection into leg muscle was not very efficient, increasing the concentration of factor IX by only 1.4 %, but it was sufficient to prevent most of the dogs' spon-taneous internal bleeding. | | | Doctors in Boston have injected DNA coding for a piece of the gene called vascular endo-thelial growth factor, which directs blood vessel growth, into the damaged, blood-starved heart muscle of human patients who have had several bypass operations but are still doing poorly. | | | Researchers at the University of Pennsylvania placed DNA coding for "insulinlike growth factor 1," a growth hormone, into disabled viruses and then injected them directly into the muscle of one hind leg of young, middle-aged, and elderly mice. |
|
http://www.chilit.org/BEAUMAN2.HTM
(293 words)
|
|
| |
| | Factor VIII & IX |
| | The final report on the Registry of Factor VIII and IX Concentrates was presented by Dr. C. | | | Barrowcliffe reported on the SSC/5 "Field Type" Collaborative Study on Concentrates, one involving F VIII, the other involving F IX, and proposed a further exercise by October 1998. | | | Mikaelsson summarized three studies on the characterization of recombinant factor VIII with and without B-domain, and high purity plasma-derived factor VIII, demonstrating equivalence of activity measured by chromogenic assay and antigen content. |
|
http://www.med.unc.edu/isth/SSC/98minutes/FactorVIII&IX.html
(1001 words)
|
|
| |
| | Bleeding Disorders |
| | Factors I, II, V, VII, VIII, IX, X, XI, XII and XIII are needed for this chain reaction to take place. | | | Inherited factor VII deficiency is a chronic, life-long disorder. | | | A deficiency in any of these factors can lead to bleeding problems, each with its own symptoms and treatments. |
|
http://www.accredohealth.net/hhs/bleeding_disorders/other.html
(1001 words)
|
|
| |
| | Factor VIII Deficiencies |
| | Factor VIII is the precursor to Factor VIIIa, which catalyzes the activation of Factor IX to IXa. | | | Other bypass agents include Factor VIIa and Factor IXa, which bypass the necessity for FVIII mediated activation of FIX. | | | Please note that this is non-specific because things like a lupus anticoagulant or treatment with heparin can also cause prolongation of the aPTT in the absence of any factor inhibitors. |
|
http://medinfo.ufl.edu/year2/coag/viiidef.html
(1079 words)
|
|
| |
| | CATHOLIC ENCYCLOPEDIA: Pope Leo XIII |
| | With regard to the Kingdom of Italy, Leo XIII maintained Pius IX's attitude of protest, thus confirming the ideas he had expressed in his pastoral of 1860. | | | Along every line of religious and educational activity they have proved no small factor in the awakening and strengthening of the Christian life of the whole country. | | | Under Leo the religious orders developed wonderfully; new orders were founded, older ones increased, and in a short time made up for the losses occasioned by the unjust spoliation they had been subjected to. |
|
http://www.newadvent.org/cathen/09169a.htm
(1079 words)
|
|
| |
| | cclement5 |
| | Cn3D presentation of thrombin, factors VII, X and IX. | | | WINDOTTER : analysis of factor XI and factor XII. | | | CATH classification of thrombin and other coagulation factors. |
|
http://www.geocities.com/cclement_us/outline7.html
(1079 words)
|
|
| |
| | Clotting Factor Deficiencies |
| | Factor IX replacement has traditionally been with prothrombin complex concentrates (PCCs) that contain factors II, VII, and X as well as IX, and were associated with thrombotic risk. | | | Factor X deficiency is a rare (1 per 1 million) autosomal recessive deficiency characterized by asymptomatic heterozygotes and by homozygotes with bleeding symptoms that correlate with factor activity. | | | Factor VII deficiency is a rare (1 per 500,000) autosomal recessive deficiency that exhibits little correlation between the bleeding risk and the factor activity. |
|
http://www.clevelandclinicmeded.com/diseasemanagement/hematology/clotting/clotting.htm
(2553 words)
|
|
| |
| | Abstract number: OC847 |
| | Among patients with high levels of factor II, IX or XI, the RR of recurrence was 0.6 (95% CI 0.2-2.1), 1.1 (95% CI 0.4-2.8) and 1.3 (95% CI 0.5-3.5) after adjustment for age, sex, duration of anticoagulation, presence of factor II G20210A or factor V Leiden, and factor VIII levels. | | | The relative risk (RR) of recurrent VTE was 0.9 (95% CI 0.8-1.2), 1.0 (95% CI 0.9-1.2) and 1.1 (95% CI 0.9-1.2) for each increase of 10 IU/dL in the plasma levels of factor II, IX or XI, respectively. | | | percentile of the study population, respectively, compared to 40 of 348 (12%), 40 of 348 (12%) and 47 of 398 (12%) patients with lower factor II, IX or XI levels. |
|
http://www.schattauer.de/abstracts/absOC847.html
(2553 words)
|
|
| |
| | abstract.asp?id=7949 |
| | We investigated whether elevated levels of coagulation factor VIII, IX and XI are risk factors for myocardial infarction (MI) in young women. | | | Elevated levels of coagulation factor VIII (F VIII:C), factor IX (F IX:C) and factor XI (F XI:C) are risk factors for venous thrombosis, but their role in arterial thrombosis is less clear. | | | We conclude that high vWF:ag levels, non-O blood group, high F VIII:C and F IX:C levels are associated with an increased risk of MI in women. |
|
http://www.blackwellpublishers.co.uk/isth2003/abstract.asp?id=7949
(2553 words)
|
|
| |
| | Coagulation Factor IX |
| | Coagulation Factor IX is an important protein in the process of hemostasis and normal blood clotting. | | | Coagulation Factor IX This webpage was created as an assignment for an undergraduate course at Davidson College. | | | One of the earliest mutated forms of Coagulation Factor IX was found to be a single-base mutation (from G to A) at nucleotide 6 in the 5' UT region, later termed the Leyden-specific region. |
|
http://www.bio.davidson.edu/Courses/Molbio/MolStudents/spring2003/WoodC/coag.html
(1166 words)
|
|
| |
| | NHF HANDI Hemophilia B Leyden Fact Sheet |
| | Hemophilia B Leyden is a form of inherited factor IX deficiency characterized by a gradual increase in factor IX levels that begins at puberty. | | | The type of hemophilia B Leyden at presentation correlates with the specific mutation in the factor IX gene. | | | Recovery from hemophilia B leyden: an androgen-responsive element in the factor IX promoter. |
|
http://www.hemophilia.org/resources/hemob.htm
(925 words)
|
|
| |
| | What is Hemophilia? |
| | Factor IX deficiency hemophilia, because Factor 9 (written Factor IX) is the blood protein which is lacking and whose absence slows down the normal clotting process. | | | Factor VIII deficiency hemophilia, because it is the lack of the Factor 8 (written Factor VIII) protein in the blood that causes the clotting problem. | | | As hemophilia is an hereditary disorder, people are affected at birth. |
|
http://www.hemophilia.ca/en/2.1.1.php
(468 words)
|
|
| |
| | Hemophilia: Bleeding and Clotting Disorders: Merck Manual Home Edition |
| | Recombinant forms of both factor VIII and IX are available; the dose, frequency, and duration of therapy are determined by the site and severity of the bleeding problem. | | | Hemophilia B is a deficiency in clotting factor IX. | | | As a result, factor replacement therapy becomes less effective. |
|
http://www.merck.com/mmhe/ag/print/sec14/ch173/ch173f.html
(602 words)
|
|
| |
| | Hemophilia B Description and Treatment |
| | This is done by a process called "factor replacement therapy." People with this type of hemophilia must inject replacement factor IX directly into their blood, a process called "infusion." | | | About 15% of people with hemophilia have hemophilia B. People with hemophilia B need to increase the level of factor IX in their blood. | | | Hemophilia B is a deficiency of factor IX. |
|
http://www.zlbbehring.ca/ab/n25240/PFDiseaseCatProd3.htm
(108 words)
|
|
| |
| | Hemophilia Village References |
| | Use of recombinant factor IX in subjects with haemophilia B undergoing surgery. | | | Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. | | | A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. |
|
http://www.hemophiliavillage.com/hcp_refrences.asp
(108 words)
|
|
| |
| | eMedicine - Factor VII : Article Excerpt by: Jeyanthi Ramanarayanan, MD |
| | Factor VIIa bound to tissue factor in the presence of calcium and phospholipids facilitates the conversion of factor IX to factors IXa and X to factor Xa. | | | This facilitates conversion of factor VII to factor VIIa. | | | Tissue factor is an intrinsic membrane glycoprotein that is normally not exposed on the surface of intact blood vessels. |
|
http://www.emedicine.com/med/byname/factor-vii.htm
(671 words)
|
|
| |
| | Morrissey Lab |
| | Activation of factor VII during alimentary lipaemia occurs in healthy adults and patients with congenital factor XII or factor XI deficiency, but not in patients with factor IX deficiency. | | | Factor VIIa/tissue factor generates a form of factor V with unchanged specific activity, resistance to activation by thrombin and increased sensitivity to activated protein C. Biochemistry 38:1829-1837, 1999. | | | The influence exerted by a restricted phospholipid microenvironment on the expression of tissue factor activity at the cell plasma membrane surface. |
|
http://tf7.org/pubsthree.htm
(1512 words)
|
|
|
